NexImmune, Inc. (NEXI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -32.34 Million USD | -106.29% |
| 2022 | 514.18 Million USD | 1093.68% |
| 2021 | -51.74 Million USD | -63.55% |
| 2020 | -31.63 Million USD | -55.86% |
| 2019 | -20.29 Million USD | -58.18% |
| 2018 | -12.83 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.32 Billion USD | 24.39% |
| 2024 Q1 | -3.07 Million USD | 42.57% |
| 2023 Q4 | -5.35 Million USD | 45.62% |
| 2023 Q3 | -9.85 Million USD | -30.23% |
| 2023 Q1 | 250.76 Million USD | 1636.9% |
| 2023 Q2 | -7.56 Million USD | -103.02% |
| 2023 FY | -32.34 Million USD | -106.29% |
| 2022 Q3 | -14.6 Million USD | 7.55% |
| 2022 Q2 | -15.79 Million USD | -5.36% |
| 2022 Q1 | -14.99 Million USD | 3.43% |
| 2022 FY | 514.18 Million USD | 1093.68% |
| 2022 Q4 | -16.31 Million USD | -11.74% |
| 2021 Q1 | -8.54 Million USD | -6.68% |
| 2021 FY | -51.74 Million USD | -63.55% |
| 2021 Q4 | -15.52 Million USD | -6.0% |
| 2021 Q3 | -14.64 Million USD | -20.23% |
| 2021 Q2 | -12.18 Million USD | -42.54% |
| 2020 Q2 | -6.93 Million USD | -9.74% |
| 2020 Q1 | -6.31 Million USD | -23.3% |
| 2020 FY | -31.63 Million USD | -55.86% |
| 2020 Q4 | -8.01 Million USD | 6.94% |
| 2020 Q3 | -8.6 Million USD | -24.21% |
| 2019 Q4 | -5.12 Million USD | 0.0% |
| 2019 FY | -20.29 Million USD | -58.18% |
| 2018 FY | -12.83 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -4147.904% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -274.703% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -5.188% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 73.94% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -101.172% |
| Better Therapeutics, Inc. | -39.76 Million USD | 18.651% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -71.443% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -75.996% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 9.68% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 10.316% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 71.758% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -1338.641% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 56.732% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 45.255% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -440.13% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -51.894% |
| Molecular Templates, Inc. | -8.12 Million USD | -298.134% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -113.112% |
| Orgenesis Inc. | -55.36 Million USD | 41.575% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -28.031% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -41358.133% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -76.845% |
| Scopus BioPharma Inc. | -11.6 Million USD | -178.595% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 94.354% |
| Statera Biopharma, Inc. | -174.4 Million USD | 81.455% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -801.46% |
| Trevena, Inc. | -40.28 Million USD | 19.719% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -56710.328% |
| Vaccinex, Inc. | -20.25 Million USD | -59.718% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -2636.153% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 36.652% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -315.888% |